跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,056 条关于
“transthyretin amyloidosis (ATTR)”
全部
1,056
临床试验
710
药物
78
机构
1
资讯
267
去年
Alnylam's Nucresiran Shows Sustained TTR Reduction in Phase 1 ATTR Amyloidosis Trial
18天前
Alnylam Presents New Data at ESC Congress 2026 Reinforcing RNAi-Powered TTR Silencing in ATTR-CM and Hypertension
去年
FDA Accepts Alnylam's Vutrisiran Application for ATTR Amyloidosis with Cardiomyopathy
去年
Alnylam's Nucresiran Shows Sustained TTR Knockdown in Phase 1 Trial, Poising for Biannual Dosing in ATTR Amyloidosis
去年
EU Approves WAINZUA (Eplontersen) for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
去年
FDA Accepts Alnylam's Vutrisiran sNDA for ATTR Amyloidosis with Cardiomyopathy
去年
Yoltech Therapeutics' YOLT-201 Shows Promise in Phase I ATTR Amyloidosis Trial
去年
YolTech Therapeutics Secures $45 Million Series B Funding to Advance In Vivo Gene Editing Pipeline
4个月前
Bayer's Investigational PET Tracer I-124 Evuzamitide Meets Primary Endpoints in Phase III Cardiac Amyloidosis Study
去年
Eplontersen (Wainzua) Recommended in England and Wales for Hereditary Transthyretin Amyloidosis
第 1 页，共 27 页
上一页
下一页
